Hutchison China MediTech Limited (NASDAQ:HCM) had its price target raised by research analysts at Canaccord Genuity to $38.00 in a report issued on Monday. The firm currently has a “buy” rating on the stock. Canaccord Genuity’s price target suggests a potential upside of 27.26% from the company’s previous close.

Separately, BidaskClub upgraded shares of Hutchison China MediTech Limited from a “hold” rating to a “buy” rating in a report on Wednesday, September 6th.

Shares of Hutchison China MediTech Limited (NASDAQ HCM) traded down 1.74% during midday trading on Monday, hitting $29.86. 54,604 shares of the stock traded hands. Hutchison China MediTech Limited has a 52 week low of $10.61 and a 52 week high of $32.03.

ILLEGAL ACTIVITY NOTICE: This piece of content was posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/16/hutchison-china-meditech-limited-hcm-earns-buy-rating-from-canaccord-genuity.html.

A number of large investors have recently added to or reduced their stakes in the business. The Manufacturers Life Insurance Company increased its position in Hutchison China MediTech Limited by 7.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 103,799 shares of the company’s stock valued at $2,420,000 after purchasing an additional 7,400 shares during the period. Baillie Gifford & Co. increased its position in Hutchison China MediTech Limited by 6.1% during the 2nd quarter. Baillie Gifford & Co. now owns 167,547 shares of the company’s stock valued at $3,905,000 after purchasing an additional 9,655 shares during the period. Renaissance Technologies LLC acquired a new stake in Hutchison China MediTech Limited during the 1st quarter valued at approximately $618,000. Wellington Management Group LLP increased its position in Hutchison China MediTech Limited by 7.4% during the 1st quarter. Wellington Management Group LLP now owns 510,826 shares of the company’s stock valued at $10,190,000 after purchasing an additional 35,053 shares during the period. Finally, JPMorgan Chase & Co. acquired a new stake in Hutchison China MediTech Limited during the 2nd quarter valued at approximately $5,102,000. 4.06% of the stock is owned by institutional investors and hedge funds.

Hutchison China MediTech Limited Company Profile

Hutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market.

Receive News & Ratings for Hutchison China MediTech Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hutchison China MediTech Limited and related companies with MarketBeat.com's FREE daily email newsletter.